

**Revised Draft agenda**  
**52<sup>nd</sup> meeting of the Biocidal Products Committee (BPC)**  
**17-18 September 2024**  
**Meeting is held virtually in Webex**

**Starts on 17 September at 10:30,  
ends on 18 September at 17:00**  
**The time is indicated in Helsinki time.**

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-52-2024

*For agreement*

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-51

BPC-M-51-2024

*For agreement*

5. – Administrative issues

5.1. Administrative issues

*For information*

6. – Work programme for BPC and procedural issues

6.1. BPC Work Programmes for active substance approval, Union  
authorisation, ED assessment and outlook for BPC

BPC-52-2024-6.1 A-D

*For information*

6.2. Update on active substance approval

*For information*

- 6.3. Update on Union Authorisation processes  
*For information*
- 6.4. Update on article 75(1)(g) mandates  
*For information*
- 6.5. Working procedure for renewal of a Union authorisation  
BPC-52-2024-6.5  
*For discussion and agreement*
- 6.6. Linguistic review of the translations of the summary of product characteristics (SPC) for renewal of a Union authorisation  
BPC-52-2024-6.6  
*For discussion and agreement*
- 6.7. Criteria to choose full evaluation in the context of renewal of a Union authorisations  
BPC-52-2024-6.7  
*For discussion and agreement*
- 6.8. Guidelines for applications on submission of applications of renewal of a Union authorisations  
BPC-52-2024-6.8  
*For discussion and agreement*
- 6.9. Working procedure for active substance approval and renewal  
BPC-52-2024-6.9  
*For discussion and adoption*

## **7. – Applications for approval of active substances\***

- 7.1. Evaluation of post-approval data submitted for icaridin for PT 19 and correction of environmental endpoint for the metabolite icaridin-acid  
*Previous discussion: WG-II-2024*  
BPC-52-2024-7.1 A-E  
*For adoption*

---

\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

## 8. – Union authorisation\*\*

### 8.1. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Transfluthrin for PT 18

*Previous discussion: WG-II-2024*

BPC-52-2024-8.1 A-F

***For adoption***

### 8.2. Draft BPC opinion on the Union Authorisation of a biocidal product family containing L-(+)-lactic acid for PT 3

*Previous discussion: WG-II-2024*

BPC-52-2024-8.2 A-E

***For adoption***

### 8.3. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Chlorocresol for PT 3

*Previous discussion: WG-II-2024*

BPC-52-2024-8.3 A, C-E

***For adoption***

## 9. – Article 75(1)(g) opinion requests

### 9.1. Draft BPC opinion on examination of efficacy tier 2 data for BIT for PT 6 & 13 (2 opinions)

*Previous discussion: EFF WG-II-2024*

BPC-52-2024-9.1 A1-2, B, C, D1-4, E1-4

***For adoption***

### 9.2. Draft BPC opinion on examination of efficacy tier 2 data for Formic acid for PT 6

*Previous discussion: EFF WG-II-2024*

BPC-52-2024-9.2 A-H

***For adoption***

### 9.3. Request for a BPC opinion on the “Evaluation of the endocrine disrupting properties of mecetronium ethyl sulphate”

BPC-52-2024-9.3 A

***For information***

---

\*\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by E).

- 9.4. Request for a BPC opinion on the "Inclusion of the use as concentrated animal skin disinfectants (PT3) by spraying by professional users (use 7.7 of the application) in the draft SPC of the Union authorisation of 'Chlorocresol based products – CID Lines NV' and relevant updates of the product assessment report and BPC opinion"

BPC-52-2024-9.4 A

*For information*

- 9.5. Request for a BPC opinion on the "Examination of alternatives to cholecalciferol and its possible use by the general public"

BPC-52-2024-9.5 A

*For information*

10. - Any other business

11. – Action points and conclusions

**Provisional time schedule for the  
52<sup>nd</sup> meeting of the Biocidal Products Committee (BPC)  
Virtual meeting in WebEx**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

**Tuesday 17 September: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)**

Items 1-5	Opening items and administrative issues
Item 6.1	BPC Work Programmes for active substance approval, Union authorisation, ED assessment and outlook for BPC
Item 6.2	Update on active substance approval
Item 6.3	Update on Union Authorisation processes
Item 6.4	Update on article 75(1)(g) mandates
Item 6.5	Working procedure for renewal of a Union authorisation
Item 6.6	Linguistic review of the translations of the summary of product characteristics (SPC) for renewal of a Union authorisation
Item 6.7	Criteria to choose full evaluation in the context of renewal of a Union authorisations
Item 6.8	Guidelines for applications on submission of applications of renewal of a Union authorisations
Item 6.9	Working procedure for active substance approval and renewal
Item 7.1	Evaluation of post-approval data submitted for icaridin for PT 19 and correction of environmental endpoint for the metabolite icaridin-acid

**Wednesday 18 September: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)**

Item 8.1	Draft BPC opinion on the Union Authorisation of a biocidal product family containing Transfluthrin for PT 18
Item 8.2	Draft BPC opinion on the Union Authorisation of a biocidal product family containing L-(+)-lactic acid for PT 3
Item 8.3	Draft BPC opinion on the Union Authorisation of a biocidal product family containing Chlorocresol for PT 3
Item 9.1	Draft BPC opinion on examination of efficacy tier 2 data for BIT for PT 6 & 13 (2 opinions)
Item 9.2	Draft BPC opinion on examination of efficacy tier 2 data for Formic acid for PT 6
Item 9.3	Request for a BPC opinion on the "Evaluation of the endocrine disrupting properties of mecetronium ethyl sulphate"
Item 9.4	Request for a BPC opinion on the "Inclusion of the use as concentrated animal skin disinfectants (PT3) by spraying by professional users (use 7.7 of the application) in the draft SPC of the Union authorisation of 'Chlorocresol based products – CID Lines NV' and relevant updates of the product assessment report and BPC opinion"

- Item 9.5 Request for a BPC opinion on the “Examination of alternatives to cholecalciferol and its possible use by the general public”
- Item 10 Any other business
- Item 11 Action points and conclusions

End of meeting

oOo